( Reuters) – Gilead Sciences Inc’s shares surged 16%in after hours trading on Thursday following a media report detailing motivating partial information from trials of the U.S. business’s speculative drug remdesivir in serious COVID-19 patients.
SUBMIT PICTURE: A Gilead Sciences Inc. workplace is displayed in Foster City, California, U.S. May 1,2018 REUTERS/Stephen Lam
A University of Chicago medical facility taking part in a research study of the antiviral medication said it is seeing rapid healings in fever and breathing symptoms, with nearly all clients discharged in less than a week, according to medical news site ST here
Gilead, in an emailed statement, stated “the totality of the information require to be evaluated in order to draw any conclusions from the trial.”
UChicago Medicine, also in an e-mail, stated “partial data from an ongoing clinical trial is by definition incomplete and should never ever be used to reason.”
The university stated information from an internal online forum for researc